Ticker brief
GPCR STRUCTURE THERAPEUTICS INC
Consumer, Non-cyclical · Biotechnology
last close
$53.45
1 day
+2.6%
14 days
+20.1%
mkt cap
$3.8B
signals 14d
26
authors 14d
6
Sentiment — last 14 days
daily mean sentiment, 2026-06-20 → 2026-07-02 · now +0.70 (−1 bearish … +1 bullish)
Who spoke6
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @2000STOCKMASTER | C | -4.19 | 14 | +0.53 |
| @bioinvestor24 | A | +1.35 | 7 | +0.24 |
| @PersimmonTI | A | -0.32 | 2 | +0.50 |
| @VistaPResearch | C | · | 1 | +0.15 |
| @Pharmdca | C | -1.50 | 1 | -0.25 |
| @Quantumup1 | C | -1.95 | 1 | +0.00 |
Recent signals26of 26 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @2000STOCKMASTER | +0.70 | Author sticks to takeover thesis for GPCR despite low volume move. | — | tweet ↗ |
| 2026-07-01 | @2000STOCKMASTER | +0.75 | GPCR wants 60. — States GPCR wants 60, implying upside target. | +2.6% | tweet ↗ |
| 2026-07-01 | @Quantumup1 | +0.00 | Cantor reiterates VKTX Overweight with $100 target and positive setup into 3Q26 data. | +2.6% | tweet ↗ |
| 2026-06-30 | @bioinvestor24 | +0.45 | Calls GPCR not a bad long-term play, with short-term risk from LLY orforglipron setbacks. | -0.4% | tweet ↗ |
| 2026-06-30 | @2000STOCKMASTER | +0.50 | Says GPCR keeps going, implying bullish momentum. | -0.4% | tweet ↗ |
| 2026-06-29 | @2000STOCKMASTER | +0.85 | VKTX or GPCR, maybe both, are about to be bought before new data — Strong forward takeover call for VKTX and GPCR before new data. | +3.4% | tweet ↗ |
| 2026-06-29 | @2000STOCKMASTER | +0.80 | GPCR VKTX SLS COGT could be bought out any day — Claims multiple biotech names could be bought out any day. | +3.4% | tweet ↗ |
| 2026-06-29 | @Pharmdca | -0.25 | Trimming biotech positions and raising cash. — Author is trimming named biotech positions after sector run-up. | +3.4% | tweet ↗ |
| 2026-06-28 | @bioinvestor24 | +0.30 | Sees obesity challenger potential but criticizes ABBV allocation and some molecules. | +7.5% | tweet ↗ |
| 2026-06-28 | @PersimmonTI | +0.45 | Notes GPCR's aleniglipron uses orforglipron base and closely held IP portfolio. | +7.5% | tweet ↗ |
| 2026-06-27 | @PersimmonTI | +0.55 | GPCR CEO claims strong GLP-1 IP moat and licensing leverage. | +7.5% | tweet ↗ |
| 2026-06-26 | @2000STOCKMASTER | +0.45 | Asks which of GPCR or VKTX goes parabolic first, implying bullish setup. | +7.5% | tweet ↗ |
| 2026-06-26 | @bioinvestor24 | +0.45 | Says obesity biotechs are undervalued, comparing KLRA and GPCR deal dynamics. | +7.5% | tweet ↗ |
| 2026-06-26 | @2000STOCKMASTER | +0.50 | IREN seems cheap; loaded calls. — Discloses loaded calls in IREN and positive view on GPCR running. | +7.5% | tweet ↗ |
| 2026-06-25 | @VistaPResearch | +0.15 | Article frames diabetes and GLP-1 drugs as reshaping diabetes care. | +10.8% | tweet ↗ |
| 2026-06-25 | @2000STOCKMASTER | +0.55 | Says VKTX weakness is temporary and it is just getting started, also tags GPCR. | +10.8% | tweet ↗ |
| 2026-06-25 | @2000STOCKMASTER | +0.45 | Says something is up in GPCR, implying positive speculation. | +10.8% | tweet ↗ |
| 2026-06-25 | @2000STOCKMASTER | +0.85 | Buy options in VKTX and GPCR for buyout upside. — Explicitly says VKTX and GPCR will be bought out and you have to buy options. | +10.8% | tweet ↗ |
| 2026-06-24 | @2000STOCKMASTER | -0.20 | Derisive comment toward GLP-1-related tickers, but stance is not fully explicit. | +11.0% | tweet ↗ |
| 2026-06-24 | @bioinvestor24 | -0.10 | Mentions volume story in VKTX and weak volume in KLRA/GPCR possibly hiding news. | +11.0% | tweet ↗ |
| 2026-06-24 | @2000STOCKMASTER | +0.45 | Calls several names cheap and says MBX takeover coming. | +11.0% | tweet ↗ |
| 2026-06-24 | @2000STOCKMASTER | +0.35 | Calls listed names a right trading setup, but no specific entry or levels. | +11.0% | tweet ↗ |
| 2026-06-23 | @bioinvestor24 | +0.35 | Mentions GPCR to MRK as desired prediction outcome. | +17.2% | tweet ↗ |
| 2026-06-23 | @bioinvestor24 | +0.00 | Speculates ABBV obesity BD interest leaves VKTX/KLRA/GPCR in play, with VKTX preferred. | +17.2% | tweet ↗ |
| 2026-06-21 | @2000STOCKMASTER | +0.45 | Names potential takeover picks in biotech names. | +20.1% | tweet ↗ |
| 2026-06-20 | @bioinvestor24 | +0.25 | Compares oral obesity peptide programs and delivery challenges across KLRA, NVO, LLY, VKTX, GPCR. | +20.1% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.